Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Phase 2

Completed

Conditions: Myeloproliferative Diseases

Interventions: Drug: Ruxolitinib
Drug: Lenalidomide
Drug: Prednisone

First Posted Date: 2011-06-17

Last Posted Date: 2024-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT01375140

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Phase 1

Recruiting

Conditions: High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Recurrent Burkitt Lymphoma
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Burkitt-Like Lymphoma With 11q Aberration
Recurrent B Acute Lymphoblastic Leukemia
High Grade B-Cell Lymphoma, Not Otherwise Specified
Refractory B Acute Lymphoblastic Leukemia
Refractory Burkitt Lymphoma
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Interventions: Biological: Blinatumomab
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Biological: Inotuzumab Ozogamicin
Drug: Methotrexate
Other: Laboratory Biomarker Analysis
Drug: Mercaptopurine
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine

First Posted Date: 2011-06-13

Last Posted Date: 2024-07-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 276

Registration Number: NCT01371630

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Z102
Other: placebo
Drug: Prednisolone
Drug: dipyridamole
Drug: Prednisone

First Posted Date: 2011-06-09

Last Posted Date: 2014-05-15

Lead Sponsor: Zalicus

Target Recruit Count: 294

Registration Number: NCT01369745

Locations: 🇺🇸
Zalicus Investigational Site, Toledo, Ohio, United States

A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

Phase 2

Terminated

Conditions: Polymyalgia Rheumatica
Inflammatory Diseases

Interventions: Drug: AIN457
Drug: ACZ885
Drug: Prednisone
Drug: Placebo

First Posted Date: 2011-06-02

Last Posted Date: 2021-09-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT01364389

Locations: 🇬🇧
Novartis Investigative Site, Westcliff-on-Sea, Essex, United Kingdom

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Other: laboratory biomarker analysis
Drug: cyclophosphamide
Radiation: fludeoxyglucose F 18
Drug: doxorubicin hydrochloride
Radiation: selective external radiation therapy
Drug: prednisone
Drug: vincristine sulfate
Radiation: yttrium Y 90 ibritumomab tiuxetan
Other: R-CHOP regimen

First Posted Date: 2011-05-25

Last Posted Date: 2024-02-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 159

Registration Number: NCT01359592

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Bronson Methodist Hospital, Kalamazoo, Michigan, United States
🇺🇸
St. Mary Mercy Hospital, Livonia, Michigan, United States

and more 237 locations

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Dexamethasone
Drug: Cytarabine
Drug: Methotrexate
Drug: 6-Mercaptopurine
Drug: Rituximab
Drug: Prednisone
Drug: L-asparaginase

First Posted Date: 2011-05-23

Last Posted Date: 2014-05-20

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 100

Registration Number: NCT01358253

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Phase 4

Completed

Conditions: Purpura, Thrombocytopenic, Idiopathic

Interventions: Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2011-05-19

Last Posted Date: 2016-04-20

Lead Sponsor: Shandong University

Target Recruit Count: 261

Registration Number: NCT01356511

Locations: 🇨🇳
Qilu Hospital, Shandong University, Jinan, Shandong, China

Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg

Phase 3

Completed

Conditions: Demyelinating Polyneuropathy

Interventions: Drug: Immunoglobulin perfusion
Drug: Prednisone

First Posted Date: 2011-05-06

Last Posted Date: 2014-09-26

Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Target Recruit Count: 40

Registration Number: NCT01349270

Locations: 🇫🇷
CHU Grenoble, Grenoble, France
🇫🇷
CHU Clermont-Ferrand, Clermont-Ferrand, France
🇫🇷
Chu Marseille, Marseille, France

and more 8 locations

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients

Phase 3

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: tacrolimus placebo
Drug: tacrolimus capsule
Drug: leflunomide placebo
Drug: leflunomide tablet
Drug: prednisone

First Posted Date: 2011-04-26

Last Posted Date: 2014-10-17

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 84

Registration Number: NCT01342016

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma
Hepatosplenic T-cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Peripheral T-cell Lymphoma

Interventions: Drug: prednisone
Drug: cyclophosphamide
Drug: etoposide
Drug: Vincristine
Drug: pralatrexate
Other: laboratory biomarker analysis
Genetic: comparative genomic hybridization
Genetic: gene expression analysis
Genetic: nucleic acid sequencing
Genetic: mutation analysis
Other: immunohistochemistry staining method
Genetic: microarray analysis
Genetic: RNA analysis

First Posted Date: 2011-04-18

Last Posted Date: 2023-09-22

Lead Sponsor: University of Nebraska

Target Recruit Count: 34

Registration Number: NCT01336933

Locations: 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy